196 related articles for article (PubMed ID: 11386413)
1. Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function.
Schagen SB; Hamburger HL; Muller MJ; Boogerd W; van Dam FS
J Neurooncol; 2001 Jan; 51(2):159-65. PubMed ID: 11386413
[TBL] [Abstract][Full Text] [Related]
2. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients.
Schagen SB; Muller MJ; Boogerd W; Rosenbrand RM; van Rhijn D; Rodenhuis S; van Dam FS
Ann Oncol; 2002 Sep; 13(9):1387-97. PubMed ID: 12196364
[TBL] [Abstract][Full Text] [Related]
3. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
4. Acute and late toxicity following adjuvant high-dose chemotherapy for high-risk primary operable breast cancer--a quality assessment study.
Svane IM; Homburg KM; Kamby C; Nielsen DL; Roer O; Sliffsgaard D; Johnsen HE; Hansen SW
Acta Oncol; 2002; 41(7-8):675-83. PubMed ID: 14651213
[TBL] [Abstract][Full Text] [Related]
5. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
6. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma.
Schagen SB; van Dam FS; Muller MJ; Boogerd W; Lindeboom J; Bruning PF
Cancer; 1999 Feb; 85(3):640-50. PubMed ID: 10091737
[TBL] [Abstract][Full Text] [Related]
7. High-dose adjuvant chemotherapy for patients with high-risk breast cancer: efficacy is still an open question.
Clin Breast Cancer; 2000 Oct; 1(3):191-2. PubMed ID: 11899643
[No Abstract] [Full Text] [Related]
8. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
van Dam FS; Schagen SB; Muller MJ; Boogerd W; vd Wall E; Droogleever Fortuyn ME; Rodenhuis S
J Natl Cancer Inst; 1998 Feb; 90(3):210-8. PubMed ID: 9462678
[TBL] [Abstract][Full Text] [Related]
9. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy.
Koppelmans V; Breteler MM; Boogerd W; Seynaeve C; Gundy C; Schagen SB
J Clin Oncol; 2012 Apr; 30(10):1080-6. PubMed ID: 22370315
[TBL] [Abstract][Full Text] [Related]
10. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Schilder CM; Eggens PC; Seynaeve C; Linn SC; Boogerd W; Gundy CM; Beex LV; Van Dam FS; Schagen SB
Acta Oncol; 2009; 48(1):76-85. PubMed ID: 18777410
[TBL] [Abstract][Full Text] [Related]
11. Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in patients with breast cancer: an electrophysiologic study.
Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; Muller MJ; van Dam FS
Clin Breast Cancer; 2006 Apr; 7(1):67-78. PubMed ID: 16764746
[TBL] [Abstract][Full Text] [Related]
12. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; van Dam FS
Breast Cancer Res Treat; 2005 Nov; 94(1):53-61. PubMed ID: 16175317
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
14. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study.
Debess J; Riis JØ; Engebjerg MC; Ewertz M
Breast Cancer Res Treat; 2010 May; 121(1):91-100. PubMed ID: 20306129
[TBL] [Abstract][Full Text] [Related]
15. Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study.
Schilder CM; Seynaeve C; Linn SC; Boogerd W; Beex LV; Gundy CM; Nortier JW; van de Velde CJ; van Dam FS; Schagen SB
Psychooncology; 2012 May; 21(5):479-87. PubMed ID: 21351188
[TBL] [Abstract][Full Text] [Related]
16. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy.
Mehnert A; Scherwath A; Schirmer L; Schleimer B; Petersen C; Schulz-Kindermann F; Zander AR; Koch U
Patient Educ Couns; 2007 Apr; 66(1):108-18. PubMed ID: 17320337
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
[TBL] [Abstract][Full Text] [Related]
19. Course of mental fatigue and motivation in breast cancer patients receiving adjuvant chemotherapy.
de Jong N; Candel MJ; Schouten HC; Abu-Saad HH; Courtens AM
Ann Oncol; 2005 Mar; 16(3):372-82. PubMed ID: 15677622
[TBL] [Abstract][Full Text] [Related]
20. Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group.
Del Mastro L; Venturini M; Lionetto R; Carnino F; Guarneri D; Gallo L; Contu A; Pronzato P; Vesentini L; Bergaglio M; Comis S; Rosso R
J Clin Oncol; 2001 Apr; 19(8):2213-21. PubMed ID: 11304774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]